SAN FRANCISCO, June 3, 2024 — Ashby, a recruiting platform that efficiently scales hiring from startup through enterprise, has raised an additional $30 million in equity financing. This round of funding comes with a vote of confidence from existing investors following a 6X growth in revenue. Lachy Groom, who also led Ashby’s seed round, led the Series C with participation from Elad Gil, F-Prime, Y Combinator, and existing Ashby customers. To date, the company has raised roughly $70M.

This latest round of financing will enable Ashby to continue its rapid pace of product development and enterprise expansion.

“At its best, fundraising accelerates something that is already going really well. We’re fortunate to have found ourselves in that position and as a result, we’ve decided to pull forward our Series C by a couple of quarters,” said Benjamin Encz, Co-Founder and CEO of Ashby.

“It’s been amazing to see Ashby’s growth and product velocity in the last few years,” said Lachy Groom, “Despite a tricky market, Ashby has 6x’d the business since the Series B and has garnered a lot of love from customers in a space that historically had really low NPS. In the current environment, more and more talent teams are looking to consolidate tools and ‘do more with less’ and Ashby, which is packed with automation and AI-enabled features, is perfectly positioned to benefit from that trend.”

“It’s the first ATS I’ve ever been impressed with,” said Veronica Salcido, Head of Global Talent at Multiverse. “We were looking for an innovative partner that was looking to build the future of talent acquisition, not one stuck in the way things had been done 10, 20 years ago. And in switching to Ashby All-in-One I got rid of a lot of vendors we no longer needed, so that made me look absolutely brilliant to my finance team.” 

About Ashby

Ashby was founded in late 2018 by Benjamin Encz and Abhik Pramanik. The company emerged from stealth mode at the time of their Series B announcement in September 2022, and have since then grown to support over 1,300 customers that range from some of the fastest growing startups in the world to some of the most cutting edge enterprises with 18K+ employees.

The product continues to differentiate on the quality and accessibility of talent team data, which serves as a foundation for seamless workflows, powers unique AI functionality that improves efficiency and personalization, and consolidates the full recruiter workflow into one system versus multiple point solutions. Layered on top is the quality of their customer experience, proprietary data reports, and commitment to the talent community.

Supporting the strong growth and ambitious product roadmap, Ashby has made a number of additional key hires including VP of People and Talent Jim Miller (15 years at Google shaping their internal ATS, GHire), VP of Finance Shane Gallaher (first FP&A hire at Fastly), VP of Customer Success Kelsey Peterson (HubSpot and early startups), Head of Support Allie Hurley (ClickUp), Head of EMEA Sales Jack Hanratty (Asana and LinkedIn), as well as a number of top talent leaders and operators.

Learn more at ashbyhq.com 
Follow our updates and trend reports on LinkedIn
Contact: [email protected]

SOURCE Ashby

SAN FRANCISCO, June 3, 2024 — Stackless Data, a leading provider of data-driven solutions, is excited to announce the release of its latest resource, “The Seller’s Playbook for Increasing CLV and Reducing CAC.” Stackless Data is offering this playbook as a free download, emphasizing the company’s commitment to empowering retailers and CPG leaders to elevate their businesses.

Recognizing that customers lie at the heart of any successful business, Stackless Data underscores the vital importance of prioritizing Customer Lifetime Value (CLV) and reducing Customer Acquisition Cost (CAC) for sustained brand success. The playbook provides a roadmap for transitioning from a traditional funnel-based sales approach to a dynamic flywheel model.

The Seller’s Playbook delves into the core principles of the flywheel sales model, showcasing how it stands in contrast to the conventional sales funnel. The flywheel model represents a shift from a linear, one-way sales process to a circular and self-reinforcing system. In essence, it views customer interactions as a continuous cycle, with each positive engagement propelling the wheel forward.

“We believe that in order to secure long-term success, retailers and CPG leaders must embrace a holistic data strategy that revolves around customer relationships,” says Nachi Mehta, CEO of Stackless Data. “The flywheel sales model introduces a more dynamic and sustainable approach, fostering customer loyalty and advocacy.”

Within the playbook, readers will gain insights into the fundamental concepts of the flywheel model and discover how it contributes to increased Customer Lifetime Value. Practical tips and strategies will be shared, allowing brands to implement actionable steps to enhance CLV while simultaneously reducing CAC.

“The Seller’s Playbook aims to be a valuable resource for businesses looking to thrive in a competitive market,” adds Mehta. “By orienting data capture and usage the flywheel sales model, retailers and CPG leaders can create a positive feedback loop that benefits both the brand and the customer.”

Stackless Data invites businesses and industry professionals to download “The Seller’s Playbook for Increasing CLV and Reducing CAC” for free https://stacklessdata.com/sellers-playbook. Empower your brand with the insights needed to forge stronger customer relationships, optimize marketing efforts, and ultimately drive sustainable growth.

About Stackless Data
Stackless Data provides a data readiness platform that empowers businesses to unlock the full potential of their data while slashing data intelligence total cost of ownership by 70% and giving lightning-fast time to value. With a commitment to efficiency, cost savings, and strategic insights, Stackless Data is at the forefront of revolutionizing the way companies approach and utilize their data.

For media inquiries, contact:
Fritz Rollins
415-846-3773
[email protected]

SOURCE Stackless Data

Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential

SAN DIEGO, June 3, 2024 — Psylo, a leading biotechnology company focused on the development of next-generation neuroplastogens, today announced at the BIO Conference in San Diego the successful first close toward an $8 million USD Series Seed financing. This funding will accelerate the advancement of PSYLO-100X, the company’s flagship non-hallucinogenic 5-HT2A agonist, poised to revolutionize the treatment of depression and other mental health disorders.

PSYLO-100X distinguishes itself from first-generation psychedelics by eliciting neuronal remodeling without causing hallucinatory effects. This breakthrough compound demonstrates antidepressant-like effects in vivo and promotes neuroplasticity in vitro, while notably avoiding activation at the 5-HT2B receptor—a critical safety feature due to the cardiotoxicity risk associated with activation of this receptor.

“We are thrilled to announce this funding milestone at the BIO Conference,” said Joshua Ismin, CEO of Psylo. “This capital raise underscores strong confidence in Psylo’s unique translational approach and the therapeutic potential of our pipeline. Our platform has yielded a non-hallucinogenic candidate designed to be safely administered at home without clinical supervision, and serves to advance our mission to address the mental health crisis for a broader patient population.”

The Series Seed financing was led by Tenmile, a leading Health investor, with participation from Palo Santo, Focalpoint Ventures (formerly Empath Ventures), Mystic Ventures, and Gaingels. Dr. Steve Burnell, Managing Director of Tenmile, expressed enthusiasm for the investment: “We have been incredibly impressed with Psylo’s progress and the innovative approach they are taking to address mental health disorders. We are pleased to be investing in Psylo and are confident in their ability to advance PSYLO-100X, which we believe has the potential to make a significant impact in the neuro space.”

Key Highlights of PSYLO-100X:

• Non-hallucinogenic: Unlike traditional psychedelics, PSYLO-100X has been designed to remove hallucinatory effects, making it a safer and more accessible treatment option.
• Partially selective 5-HT2A agonist: PSYLO-100X selectively targets the 5-HT2A receptor without activating the 5-HT2B receptor, reducing the risk of cardiotoxicity.
• Promotes neuroplasticity: Increases the complexity of neurons in cell culture, suggesting potential for long-term therapeutic benefits.
• Antidepressant effects: Demonstrative pro-cognitive effects in vivo, offering a promising new treatment for depression, anxiety, and other ruminative disorders.

“After three years of rigorous drug-discovery, we’re hugely encouraged by our progress,” noted Dr. Samuel Banister, Chief Scientific Officer at Psylo. “PSYLO-100X is a non-tryptamine, non-phenethylamine compound with a hugely promising preclinical profile. We believe this novel approach marks a significant leap forward in developing safer, more effective treatments.”

Psylo plans to utilize the Series Seed funds to continue to invest in their drug discovery platform, and advance PSYLO-100X through IND enabling studies, with the goal of initiating first in human clinical trials in 2025.

Founded in Australia, Psylo recently restructured to become a US Delaware C-corp in-line with the fundraise, and has established labs at the University of Colorado Boulder and the University of New South Wales in Sydney. For more information about Psylo and its groundbreaking work in neuroplastogens, visit www.psylo.bio

About Psylo

Psylo is a biotechnology company dedicated to developing next-generation neuroplastogens to treat mental health disorders. By leveraging cutting-edge science and innovative therapeutic approaches, Psylo aims to transform the mental health landscape and improve the lives of millions worldwide.

SOURCE Psylo

CHARLOTTESVILLE, Va., June 3, 2024 — Caju AI, a leading innovator in Generative AI-powered solutions for customer engagement, is pleased to announce the successful closure of a $3 million Seed financing round. This strategic investment is backed by Grotech Ventures, Felton Group, the family office of Charlottesville, VA based hedge fund manager Jaffray Woodriff, and angel investors. This funding milestone propels Caju AI into a new phase of growth and innovation, reinforcing its position as a leader in AI-driven customer engagement and compliance solutions.

Empowering Next-Generation Customer Engagement

Caju AI’s platform, renowned for its robust Generative AI capabilities, securely captures and analyzes customer communications across all messaging channels as well as customer engagement data to deliver advanced analytics for conversation intelligence, call summaries, regional activity monitoring, key trend analysis, and actionable business intelligence, all designed to accelerate field engagement and enhance customer satisfaction across the enterprise. At the same time, Caju AI ensures regulatory compliance, prevents data loss, and mitigates other risk concerns.

“Most enterprises do not have visibility into digital conversations or understand all customer interactions across their organization, either for business insights or risk protection. Our platform delivers a highly innovative, Gen AI-driven conversation intelligence solution to provide enterprise-level analysis as a comprehensive end-to-end solution,” said Otavio Freire, CEO and Co-Founder of Caju AI.

Strategic Investment for Future Growth

The investment from Grotech Ventures and Felton Group underscores the confidence in Caju AI’s vision and technological prowess. Grotech Ventures, renowned for backing transformative tech companies, and Felton Group, the early-stage investment arm of AI hedge fund titan Jaffray Woodriff, bring capital and strategic expertise to accelerate Caju AI’s market expansion.

“Caju AI is at the forefront of a tech revolution that empowers organizations to harness the full potential of Generative AI while ensuring compliance and security,” said Steve Fredrick, Partner at Grotech Ventures. “We are thrilled to support their journey and witness the transformative impact they will have on customer interaction.”

About Caju AI

The Caju AI platform assists organizations in capturing communications and customer engagement data while ensuring privacy, security, and compliance. Utilizing the remarkable capabilities of generative artificial intelligence to comprehend human conversations, Caju AI quickly analyzes messaging and customer records across the organization on a large scale. It delivers actionable intelligence that empowers teams to provide exceptional customer service, foster stronger relationships, and drive superior business results. The Caju platform is rapidly becoming essential for the financial services, pharmaceutical, healthcare, education, and government sectors.

For more information, visit Caju AI

About Grotech Ventures

Grotech Ventures is a leading early-stage venture capital firm with a history of backing innovative technology companies. With a focus on enterprise software, security, and digital media, Grotech Ventures partners with visionary entrepreneurs to build market-leading businesses.

About Felton Group

Felton Group, the family office of Jaffray Woodriff, is dedicated to investing in early-stage technology companies with a focus in Charlottesville and Central Virginia. With a strong track record of supporting transformative businesses, Felton Group is pivotal in fostering innovation and growth.

SOURCE Caju AI

TEL AVIV, Israel, June 3, 2024 — Zero Candida (the “Company” or “ZC “) an Israeli FemTech medical device start-up is pleased to announce that it is in the process of applying to the TSX Venture Exchange in Canada to list its shares at a proposed valuation of 40 million Canadian dollars.

About Zero Candida:

ZC is a private FemTech technology company incorporated under the corporate laws of the State of Israel. ZC is developing an AI smart tampon-like device based on AI on a therapeutic light source with a selected wave-length and intensity that can treat the Candida fungus with successfully of 99.999% an POC. Vulvo-Vaginal Candidiasis (“VVC”) affects about 75% of women globally, each year 138 million women are affected world-wide and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments and constitutes up to 10% of the cases of VVC. Existing treatments are unable to overcome the high rate of recurrence, since the root cause of the condition is poorly understood and addressed.

ZC has signed pre-clinical agreements with hospitals in Israel and Europe and the company has successfully completed a safety trial for the use of a pre-clinical device in large animals (sheep) ZC continues the development of the final product for human use in preparation for a clinical trial that took place in June 2025.

Zero Candida’s device will bring the field of gynecology into the 21st century with hybrid medicine and technology-based diagnostics. At the same time as developing the treatment procedure, Zero Candida is working on creating a technology to enable the hybrid medicine services to be provided by gynecologists to populations that until now received no treatment at all, including, among others, in the developing countries.

Summary of Transaction

Pursuant to the business combination agreement (the “Agreement”) between a Canadian reporting issuer (the “Reporting Issuer”) and the Company, the transaction is expected to be contemplated by a three-cornered amalgamation, where the Reporting Issuer’s wholly owned Israeli subsidiary incorporated solely for the purpose of the transaction, is expected to amalgamate with ZC. Each holder (each a ” ZC Shareholder”) of ZC Share, other than a ZC Shareholder who exercised Dissent Rights (as defined in the Israeli Companies Law) is expected to receive 8.6277 eight and six thousand two hundred seventy seven ten-thousandths) shares in the capital of the Reporting Issuer (each a “Resulting Issuer Share”) in exchange for each ZC Share held by such ZC Shareholder, resulting in the Company issuing up to an aggregate of 12,223,232 Resulting Issuer’s Shares (which will represent approximately 85.94% of the issued and outstanding Resulting Issuer Shares, without taking into consideration any ZC share purchase warrants to be exercised immediately prior to completion of the Transaction, stock options or a concurrent financing). Additionally, the holders of stock options of ZC will be entitled to receive Resulting Issuer Shares, instead of ZC Shares, on the exercise of their options.

Eli Ben Haroosh, Founder & CEO: “Zero-Candida’s technology is a game changer that will change the treatment of women and FemTech industry in the world. Zero Candida’s technology, first of its kind using a controlled “Blue Light”, destroys the fungus at record speed and without side effects. The treatment is carried out by a tampon-like medical device which, according to medical experts, provides an optimal solution for removing the fungus altogether, preventing the recurrence of the disease. Another significant advantage of the Zero Candida device is treatment without side effects, in a world where many of us try to improve our health without the use of chemicals. We foresee an amazing future for Zero Candida in the medical devices’ world. Zero Candida has a potential to become a technological leader and using its ground-breaking technology to expand boundaries of non-chemical candida treatment”.

Dr. Asher Holtzer, Director: “the invention of Zero Candida can potentially become a game changer in the world, the company brings amazing news to FemTech women’s care and can become a leader in women’s health all over the world. According to studies in the world, 3 out of 4 women, approximately 75%, suffer during their lifetime from Candida disease, a fungal infection that attacks large parts of the female reproductive system, which causes significant damage to the quality of life and, in severe cases, even disability. Until now, the common treatments for candida included antifungal drugs that alleviated the symptoms but failed to solve the problem at its root”.

Contact:
Eli Ben Haroosh, CEO & Founder
E: [email protected]
Website : www.Zero-Candida.com
Facebook: @Zero-candida

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements

This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Zero Candida. Readers are cautioned not to place undue reliance on forward-looking statements.

Logo – https://mma.prnewswire.com/media/2420533/4723164/ZERO_CANDIDA_Logo.jpg

SOURCE Zero Candida

VICTORIA, Seychelles, May 31, 2024 — Leading digital asset exchange Bitrue is set to launch its first Launchpool on May 31, 2024, in a significant move following the successful launch of Bitrue Ventures earlier this week. By participating in Bitrue Launchpool, up-and-coming projects can gain instant access to Bitrue’s large international user base of over 9 million users, boost their market presence, and enhance the potential value of their token. At the same time, users can earn new token rewards by simply staking their existing BTR, USDT, or other tokens.

Stringent Selection Process to Ensure Project Quality

Bitrue will conduct a rigorous vetting process for projects that intend to participate in Bitrue’s Launchpool to ensure that only high-quality and high-potential projects are selected,” said Robert Quartly-Janeiro, Bitrue’s Chief Strategy Officer & Spokesperson. “In the volatile world of digital asset markets, Bitrue’s Launchpool aims to be a low-risk offering that offers users both stability and potential returns.”

Robert mentioned that the Launchpool has been designed with UX in mind, prioritizing security with the return of staked assets and rewards at the end of the staking period. Users will be able to manage their participation with the flexibility to un-stake at any time, with hourly reward calculations and distributions minimizing risks of impermanent loss. Bitrue Launchpool is a cost-effective staking option with no ‘gas’ or processing fees. Additionally, users can start earning rewards by staking existing asset holdings.

Bitrue Ventures Empowers Early-Stage Projects

Earlier this week, Bitrue announced the launch of Bitrue Ventures, with a focus on AI and real-world asset (RWA) projects. Bitrue Ventures plans to invest capital starting from $50,000 to $200,000 per project. Through the newly launched investment arm, Bitrue will be able to support promising projects early on and empower them through the Launchpool, which Bitrue’s user base can provide an immediately established and engaged community for these projects. This plays an integral role in Bitrue’s project support program.

N.B. Bitrue has yet to reveal the specific cryptocurrencies available for staking. Users can stay tuned to Bitrue’s official X account for further details, including the first list of featured projects. Additionally, projects interested in participating in Launchpool can contact Bitrue at [email protected].

SOURCE Bitrue

BOSTON, 30 mai 2024 — Chloris Geospatial, l’entreprise technologique leader dans la mesure du carbone forestier depuis l’espace, accueille la Fondation Cisco et NextSTEP en tant qu’investisseurs. Les deux nouveaux venus rejoignent les investisseurs existants AXA IM Alts, Orbia Ventures, At One Ventures et Counteract dans le cadre d’un nouveau cycle de financement qui soutiendra l’avancement continu de la mission de Chloris.

La conservation et la restauration des forêts sont des solutions vitales à la crise du changement climatique et de la biodiversité, et un outil nécessaire pour orienter l’économie mondiale vers des émissions nettes nulles d’ici 2050. Les technologies de surveillance de Chloris permettent d’étendre ces solutions en évaluant leur impact sur le terrain en toute confiance.

Développée sous la direction de son cofondateur et directeur scientifique, Alessandro Baccini, la technologie de Chloris produit des estimations annuelles fiables de la densité de la biomasse et quantifie le stock de carbone forestier et son évolution pour toute zone d’intérêt en utilisant des données d’observation de la terre, la fusion de capteurs exclusifs et des algorithmes d’apprentissage automatique. La technologie de Chloris permet aux gouvernements, aux entreprises, aux organisations de la société civile, aux peuples autochtones et aux communautés locales de suivre toutes les dynamiques de la biomasse, y compris celles résultant de la déforestation, de la dégradation et de la croissance des arbres, de l’échelle du terrain à l’échelle continentale, et de comprendre l’impact de leurs projets de carbone forestier et de leurs chaînes d’approvisionnement.

Le nouveau cycle de financement permettra à Chloris de répondre aux besoins évolutifs du marché, tout en facilitant une croissance commerciale continue et en consolidant la position de Chloris en tant que nom le plus fiable en matière de télédétection pour la comptabilisation du carbone forestier.

« Nous sommes ravis d’avoir obtenu le soutien continu de nos investisseurs existants et nous souhaitons la bienvenue à la Fondation Cisco et à NextSTEP, a déclaré Marco Albani, cofondateur et PDG de Chloris. Cet investissement réaffirme la confiance de nos investisseurs et leur engagement dans notre mission de fournir des données de haute intégrité sur l’impact de la nature et de l’action climatique. »

Chloris a également annoncé aujourd’hui qu’Adam Gibbon, responsable du capital naturel chez AXA IM Alts, a rejoint son conseil d’administration.

« Nous pensons que la technologie de Chloris est un bond en avant, qui permet de mesurer la biomasse forestière à une échelle, une vitesse et une précision inégalées, et nous nous attendons à ce qu’elle devienne la norme de facto pour les projets de carbone forestier et l’empreinte de la chaîne d’approvisionnement. Cet investissement contribue à la mission d’AXA IM Alts d’investir dans des activités et des solutions qui assurent la protection, la restauration et la gestion durable du capital naturel », a commenté Adam Gibbon, responsable du capital naturel chez AXA IM Alts.

« Grâce aux investissements climatiques de la Fondation Cisco, nous nous efforçons de soutenir les entreprises climatiques en phase de démarrage qui peuvent avoir un impact substantiel sur le climat, a expliqué Elias Habbar-Baylac, investisseur climatique auprès de la Fondation Cisco. Notre soutien à Chloris Geospatial s’explique par sa capacité exceptionnelle à surveiller la dynamique du carbone forestier avec précision et à grande échelle. La technologie avancée de fusion de capteurs et les modèles d’apprentissage automatique de Chloris fournissent des données essentielles pour une gestion robuste et évolutive des puits de carbone naturels, s’alignant sur la stratégie de la Fondation Cisco visant à protéger et à augmenter les puits de carbone naturels. » La Fondation Cisco a été créée en 1997 grâce à un don de Cisco. En 2021, la Fondation Cisco s’est engagée à verser 100 millions de dollars au cours des 10 prochaines années pour financer des solutions climatiques innovantes.

« Notre investissement stratégique dans Chloris, une décision prise en accord avec notre mission et nos valeurs, reflète le rôle critique des technologies de surveillance fiables dans la lutte efficace contre le changement climatique », a souligné Claudio Colombo, directeur général de NextSTEP. NextSTEP (NextEnergy Sustainable Technology for the Planet) est une initiative d’investissement promue par NextEnergy Group et dédiée aux investissements de pré-amorçage et d’amorçage dans les startups CleanTech.

« Les solutions basées sur la nature sont des éléments essentiels dans les efforts de l’humanité pour réduire le carbone dans l’atmosphère. Orbia Ventures a passé de nombreux mois à évaluer le marché de la télédétection avant de décider d’investir dans Chloris. Avec la meilleure équipe du secteur, Chloris est la seule entreprise au monde capable de mesurer de manière rentable et à grande échelle les stocks de carbone et les changements dans toutes les forêts du monde depuis l’an 2000 », a ajouté Shai Albaranes, vice-président de l’innovation et du capital-risque chez Orbia.

À propos de Chloris Geospatial

Chloris Geospatial est un fournisseur de premier plan d’informations fiables sur le carbone forestier, qui s’appuie sur l’intelligence artificielle et l’apprentissage automatique pour créer des solutions innovantes qui génèrent de la valeur pour les entreprises. La technologie aide les entreprises à prendre des décisions éclairées et à améliorer leurs opérations grâce à des informations évolutives et rentables qui maximisent les fonds pour agir sur le terrain.

Pour en savoir plus, rendez-vous sur www.chloris.earth.

Logo – https://mma.prnewswire.com/media/2424680/Chloris_Geospatial_Logo.jpg

SAN FRANCISCO, May 30, 2024 — Today, Dialogue announces the launch of its innovative app designed for the creation and monetization of AI-powered digital clones and imaginary characters. The app enables influencers, content creators, actors, celebrities, and educators to build their AI clones with just a few clicks and start monetizing them immediately.

As of today, the monetization functionality is available to all content creators registered within the app upon request. The Dialogue team will respond to everyone who wants to start a monetization account and will help set up the account and create a digital clone or an AI character.

Powered by cutting-edge open-source language models and proprietary GenAI algorithms, Dialogue offers a seamless user experience with advanced lip-sync and high-performance video generation capabilities. It is the first app to offer a truly customized dialogue experience with digital clones of influencers and celebrities in real-time via video messages, setting a new industry standard.

Dialogue offers a Freemium monetization model that provides subscribers of the Pro version the opportunity to interact with the digital clones of their favorite people and characters anytime via personalized video messages. This feature caters to the growing demand for direct and personal communication in digital fan engagement.

Angela Henderson, a model, dancer, and content creator from LA, shares her experience with Dialogue App: “It’s a really fun and innovative idea. It creates a connection and a new experience for my fans to explore. The idea of having a twin in a digital form is an awesome idea and so futuristic. I’m excited to be a part of this and I’m sure my fans will too. I believe this is the future of blogging.”

Since the soft launch of a test version of the app 7 months ago, Dialogue has attracted 1.04 million early adopters with 150,000 monthly active users (MAU) and more than 10,000 paid users (PMAU). Now, Dialogue has 10 times higher average revenue per users (ARPU) than Character.ai. Most of the current Dialogue users are males aged 35-40, who are single or feel lonely even in relationships. The app’s growing popularity underscores a trend predicted by CB Insight for 2024 – an explosion in AI friendships and companionship apps.

“We live in the time of the epidemic of loneliness, which began even before the COVID-19 pandemic,” says Jura Fitzgerald, Dialogues’ Founder and CEO. “In 1960, single-person households accounted for only 13% of all U.S. households. By 2022, that number had more than doubled, to 29%, according to the USDHHS. People are spending more free time alone than ever. We have built an AI-powered tool to help fill this gap, giving people a way to communicate with clones of their favorite actors and influencers, which would be nearly impossible in the physical world. Dialogue can also serve as a social skills training tool, emotional support buddy, or as an educational app allowing conversations with historical figures or book characters.”

Dialogue advocates for the responsible and safe use of AI, adopting a human-centric approach and promoting ethical practices in the use of generative algorithms. AI-powered scripts manage content moderation, with human moderators intervening when necessary. To prevent user confusion and the spread of deep fakes, any video reposted elsewhere is clearly marked as AI-generated.

“Our team upholds strict digital personality protection standards and will suspend any user who exploits someone else’s personality, deleting their infringing content,” adds Fitzgerald.

Contact:

Svitlana Rahimova
PR and Communications at Dialogue
[email protected]
408-603-1710

SOURCE Dialogue

BANGKOK, May 30, 2024 — Disrupt Technology Venture (“Disrupt”) announced the introduction of Disrupt Health Impact Fund with the first group of co-investment partners from leading Thai business companies – Digital Health Ventures (“DHV”), the innovation and venture arm of Samitivej Hospital Group, Thana Asset Company Limited (“THANA”), Saha Pathana Inter-Holding Public Company Limited (“SPI”) and Sripatum University (“SPU”). Disrupt Health Impact Fund is dedicated in providing Thailand’s healthcare sector with access to world-class deep technology (DeepTech) and improving healthcare services for the Thai people. Managed by an experienced team that oversees over 6 funds which have invested in 134 companies across 16 countries, the fund plans to invest in DeepTech companies in the healthcare field, both domestically and internationally. This initiative aims to enhance the healthcare ecosystem, giving Thai people access to world-class health technologies.

Mr. Krating Poonpol, Chairman of Disrupt Health Impact Fund revealed “The healthcare market, valued at over US$9 trillion or more than 330 trillion Thai baht, represents a trillion-dollar industry and a mega trend that will gain even greater importance in the future.”

Ms. Jantanarak Tuekaew, Partner of Disrupt Health Impact Fund added that, “Thailand has been ranked among the top ten in terms of health security and medical tourism. This presents an opportune moment for both Thai and foreign entrepreneurs. Disrupt Health Impact Fund is committed to investing in five key areas: Self Care, Preventive Care, Silver Age, Holistic Wellness, and Smart Hospital. The fund also aims to be the gateway to Southeast Asia for DeepTech companies in the healthcare sector by leveraging healthcare expertise from both public and private sectors.”

Mr. Pithon Vithayasricharoen, Managing Director of Digital Health Ventures (“DHV”), the innovation and venture arm of Samitivej Hospital Group, said “Our experience in healthcare services has highlighted opportunities in early care and risk care. We believe that technology is the key to keeping people healthy and reducing dependence on medical professionals. Disrupt Health Impact Fund’s mission aligns with DHV to benefit society by merging our partners’ expertise to positively impact the country.”

Disrupt Health Impact Fund is managed by an experienced team led by Mr. Krating Poonpol, Ms. Jantanarak Tuekaew and Ms. Naranpat Thitipattakul. Collectively, they have overseen 6 Accelerator and VC funds, including 500 TukTuks, ORZON Ventures, Stormbreaker Ventures, and KXVC.

For more information about Disrupt Health Impact Fund: https://www.disruptignite.com/impactfund

Photos:
https://drive.google.com/drive/folders/1aygw0WU2sR5vpdmrXTMj96hiW8ZCBFYX